Sakar Healthcare Limited

rs. 7

cale up to commercial batches based on partner requirements. Sakar License out developed CTD dossiers. 7 Sakar’s Go-To Market Strategy MODELS MARKETS PRODUCTS Licensing & Supply Agreement Contract D

2x

Technology Diversified model: LSA, CDMO, CRAMS, tech transfer, profit sharing Oncology delivers ~2x higher margins vs. general formulations Shift towards own brand exports (70%) enhancing profitab

70%

g Oncology delivers ~2x higher margins vs. general formulations Shift towards own brand exports (70%) enhancing profitability Advanced Flow Chemistry (Vapourtech, UK) and GEA granulation lines Tof

rs,

y presents one of the most compelling opportunities in pharmaceuticals—defined by high entry barriers, limited competition, and superior profitability. For Sakar, entering the oncology space is not mer

1.46 million

incidence -In India, projected numbers for cancer patients is expected to rise from approximately 1.46 million in 2022 to 1.57 million in 2025. E oncology drugs market is a major segment, with a projected va

1.57 million

ected numbers for cancer patients is expected to rise from approximately 1.46 million in 2022 to 1.57 million in 2025. E oncology drugs market is a major segment, with a projected value of $7.8 billion by 20

7.8 billion

to 1.57 million in 2025. E oncology drugs market is a major segment, with a projected value of $7.8 billion by 2030. E NGS (Next-Generation Sequencing) market, particularly for targeted and gene panel seq

18%

cularly for targeted and gene panel sequencing, is also experiencing rapid growth, with a CAGR of 18% from 2024 to 2030. Growing awareness about cancer, early detection, and the use of advanced diagn

12.3 MT

e 32 ready for global launch 11 Marketing Authorisations (MAs) granted in EU and worldwide APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyoph

97 million

launch 11 Marketing Authorisations (MAs) granted in EU and worldwide APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyophilized – 22,000 vials per

29 million

Authorisations (MAs) granted in EU and worldwide APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyophilized – 22,000 vials per cycle (10 ml) Key

13 million

ldwide APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyophilized – 22,000 vials per cycle (10 ml) Key Differentiators Vertically integrated fr

“Growing CDMO/CRAMS Partnerships 05 Sustainability & Green Manufacturing Outsourcing by global pharma expected to grow at 10–12% CAGR, enhancing manufacturing scalability.”

Portfolio Strength

1

Facility

1

Company

1

Investor Relations Advisors

1

Facility

• • • • Bavla, Gujarat – EU-GMP approved, vertically integrated oncology plant Product Capability: Oral solids, oral liquids, sterile injections (liquid & lyophilised), and oncology APIs (De- Dietrich glass reactors for complex oncology molecules) R&D Excellence: Integrated F&D, ADL, and R&D labs equipped with Flow Chemistry (Vapourtec, UK) Innovation Focus: Liposomal, HME- based, and cytotoxic oral liquid formulations to enhance patient compliance and bioavailability 55 oncology products developed in- house 32 ready for global launch 11 Marketing Authorisations (MAs) granted in EU and worldwide APIs – 12.3 MT Oral solids – 97 million tablets, 29 million capsules Sterile injectables – 13 million vials Lyophilized – 22,000 vials per cycle (10 ml) Key Differentiators Vertically integrated from API to Finished Dosage High containment (OEL Level 4) facility ensuring safety and compliance Green Chemistry adoption for energy efficiency and waste reduction Technology Transfer & Scale- Up read

Company

Sakar Healthcare Limited CIN: L24231GJ2004PLC043861 Email – info@sakarhealthcare.com cs@sakarhealthcare.com

Investor Relations Advisors

MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Service Mr. Nikunj Seth nikunj.seth@in.mpms.mufg.com sejal.bhattar sejal.bhattar Mr. Sejal Bhattar sejal.bhattar@in.mpms.mufg.com Meeting Request Link LinkLink Link